Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Etelcalcetid (sekundärer Hyperparathyreoidismus): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-25. [Etelcalcetide (secondary hyperparathyroidism) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 535. 2017 Indexing Status Subject indexing assigned by CRD MeSH Humans; Hyperparathyroidism, Secondary; Parathyroid Hormone Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32017000352 Date abstract record published 18/09/2017 |